| ROP |
Report |
Adjusted diluted EPS |
IN-LINE |
pred ~$5.31 vs. cons $5.29 |
MEDIUM |
| ROP |
Report |
Revenue |
IN-LINE |
pred ~$2.11B vs. cons $2.10B |
MEDIUM |
| ROP |
Report |
Organic revenue growth |
MISS |
pred ~4.0% vs. cons 4.5% |
MEDIUM |
| ROP |
Guide |
FY26 adjusted diluted EPS guidance |
BETTER |
guide ~$21.93 vs. cons $21.90 (FY26) |
MEDIUM |
| ROP |
Guide |
FY26 total revenue growth guidance |
UNCHANGED |
guide ~8.0% vs. cons 8.1% (FY26) |
HIGH |
| ROP |
Guide |
FY26 organic revenue growth guidance |
UNCHANGED |
guide ~5.5% vs. cons 5.5% (FY26) |
MEDIUM |
| ROP |
Return |
Day-1 residual (stock − beta × S&P 500) |
+2.0% |
— |
MEDIUM |
| ROP |
Return |
5-day cumulative residual |
+0.8% (FADE) |
A clean EPS/revenue result and preserved FY26 outlook (~$21.93 vs. cons $21.90) should produce an initial relief move, but the softer organic result (~4.0% vs. cons 4.5%) and unchanged 5.5% organic-growth framework leave little out-period estimate upside. |
MEDIUM |